DE10250646A1 - Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents - Google Patents

Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents Download PDF

Info

Publication number
DE10250646A1
DE10250646A1 DE10250646A DE10250646A DE10250646A1 DE 10250646 A1 DE10250646 A1 DE 10250646A1 DE 10250646 A DE10250646 A DE 10250646A DE 10250646 A DE10250646 A DE 10250646A DE 10250646 A1 DE10250646 A1 DE 10250646A1
Authority
DE
Germany
Prior art keywords
composition according
melatonin
biotin
active ingredients
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10250646A
Other languages
German (de)
Inventor
Hans W. Dr. Schmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASAT AG Applied Science and Technology
Original Assignee
ASAT AG Applied Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASAT AG Applied Science and Technology filed Critical ASAT AG Applied Science and Technology
Priority to DE10250646A priority Critical patent/DE10250646A1/en
Priority to ES03769477.5T priority patent/ES2353865T5/en
Priority to AU2003283327A priority patent/AU2003283327A1/en
Priority to RU2005116263/15A priority patent/RU2336873C2/en
Priority to CNA2003801023960A priority patent/CN1708331A/en
Priority to BR0315878-0A priority patent/BR0315878A/en
Priority to US10/533,517 priority patent/US20060035924A1/en
Priority to CA002504361A priority patent/CA2504361A1/en
Priority to CN2011101545581A priority patent/CN102283835A/en
Priority to EP03769477.5A priority patent/EP1562585B2/en
Priority to NZ539871A priority patent/NZ539871A/en
Priority to PCT/EP2003/012097 priority patent/WO2004039454A1/en
Priority to CNA200380102359XA priority patent/CN1708301A/en
Priority to PT03775265T priority patent/PT1569724E/en
Priority to AT03769477T priority patent/ATE489073T1/en
Priority to AT03775265T priority patent/ATE419038T1/en
Priority to CN2009102541491A priority patent/CN101897736A/en
Priority to ES03775265T priority patent/ES2315541T3/en
Priority to PT03769477T priority patent/PT1562585E/en
Priority to DK03769477.5T priority patent/DK1562585T3/en
Priority to PCT/EP2003/012099 priority patent/WO2004039369A1/en
Priority to US10/533,516 priority patent/US8062648B2/en
Priority to EP03775265A priority patent/EP1569724B1/en
Priority to JP2005501815A priority patent/JP2006510556A/en
Priority to NZ539872A priority patent/NZ539872A/en
Priority to AU2003278164A priority patent/AU2003278164A1/en
Priority to JP2005501814A priority patent/JP2006513255A/en
Priority to SI200331508T priority patent/SI1569724T1/en
Priority to PL376226A priority patent/PL224878B1/en
Priority to MXPA05004535A priority patent/MXPA05004535A/en
Priority to DE50313285T priority patent/DE50313285D1/en
Priority to CA002504341A priority patent/CA2504341A1/en
Priority to BR0315927-2A priority patent/BR0315927A/en
Priority to MXPA05004537A priority patent/MXPA05004537A/en
Priority to RU2005116264/15A priority patent/RU2336890C2/en
Priority to SI200331934T priority patent/SI1562585T1/en
Priority to DK03775265T priority patent/DK1569724T3/en
Priority to KR1020057007293A priority patent/KR100849916B1/en
Priority to KR1020057007281A priority patent/KR20050083836A/en
Priority to DE50311024T priority patent/DE50311024D1/en
Priority to PL375507A priority patent/PL212984B1/en
Publication of DE10250646A1 publication Critical patent/DE10250646A1/en
Priority to IS7820A priority patent/IS7820A/en
Priority to TNP2005000118A priority patent/TNSN05118A1/en
Priority to TNP2005000117A priority patent/TNSN05117A1/en
Priority to IL168288A priority patent/IL168288A/en
Priority to IL168287A priority patent/IL168287A/en
Priority to HR20050385A priority patent/HRP20050385A2/en
Priority to HR20050386A priority patent/HRP20050386A2/en
Priority to CR7819A priority patent/CR7819A/en
Priority to NO20052494A priority patent/NO334680B1/en
Priority to NO20052490A priority patent/NO335547B1/en
Priority to EC2005005820A priority patent/ECSP055820A/en
Priority to EC2005005819A priority patent/ECSP055819A/en
Priority to HK05107183.7A priority patent/HK1074793A1/en
Priority to US12/116,484 priority patent/US8017645B2/en
Priority to CY20111100147T priority patent/CY1111179T1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87—Application Devices; Containers; Packaging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

New compositions (I) contain as active agents (a) melatonin (or a derivative), (b) Gingko biloba and (c) biotin.

Description

Die vorliegende Erfindung betrifft eine Zusammensetzung, die als Wirkstoffe eine Kombination von Melatonin, Ginkgo Biloba und Biotin enthält. Die Zusammensetzung eignet sich insbesondere zur Herstellung von Formulierungen für die topische Anwendung im Haar.The present invention relates to a composition that contains a combination of melatonin, Contains ginkgo biloba and biotin. The composition is particularly suitable for the production of Wording for topical application in hair.

Die Verwendung von Melatonin zur positiven Beeinflussung des Haarwachstums ist bekannt. Melatonin besitzt dank der selektiven Interaktion mit proliferierenden Zellen der Haarfollikel, welche das Wachstum der Haare steuern, eine stimulierende Wirkung auf das Haarwachstum. Diese stimulierende Wirkung kann bei der Verwendung verschiedener Konzentrationen an Melatonin beobachtet werden.The use of melatonin for It is known to positively influence hair growth. melatonin possesses thanks to the selective interaction with proliferating cells the hair follicle, which controls hair growth, has a stimulating effect on hair growth. This stimulating effect can be in use different concentrations of melatonin can be observed.

Überraschenderweise wurde im Rahmen der zur vorliegenden Erfindung führenden Untersuchungen festgestellt, dass der Zusatz von Ginkgo Biloba und Biotin bei gleichzeitiger Anwendung mit Melatonin die Wirkung von Melatonin verstärken und die Retention von Melatonin auf der Kopfhaut-Oberfläche erhöht wird.Surprisingly was determined in the course of the investigations leading to the present invention, that the addition of ginkgo biloba and biotin at the same time Use with melatonin to increase the effect of melatonin and the retention of melatonin on the scalp surface is increased.

Ein Gegenstand der vorliegenden Erfindung ist somit eine Zusammensetzung, die als Wirkstoffe (a) Melatonin oder ein Derivat davon, (b) Ginkgo Biloba als Extrakt oder/und einen oder mehrere Inhaltsstoffe davon und (c) Biotin enthält. Die Zusammensetzung ist vorzugsweise eine topische Formulierung, die für pharmazeutische oder/und kosmetische Anwendungen geeignet ist.An object of the present invention is thus a composition that is active as (a) melatonin or a derivative thereof, (b) ginkgo biloba as an extract and / or one or contains several ingredients thereof and (c) biotin. The Composition is preferably a topical formulation that for pharmaceutical or / and cosmetic applications is suitable.

Die erfindungsgemäße Zusammensetzung enthält eine Kombination von Wirkstoffen. Die erste Komponente dieser Kombination ist Melatonin oder ein Melatoninderivat. Melatoninderivate werden vorzugweise ausgewählt aus 5-Methoxytryptamin, 5-Methoxytryptophan, 5-Methoxytryptophol, 5-Methoxyindol-3-essigsäure und 6-Hydroxy-Melatonin. Neben diesen Substanzen können auch physiologisch akzeptable Salze, Ester und Komplexverbindungen davon eingesetzt werden.The composition according to the invention contains a Combination of active ingredients. The first component of this combination is melatonin or a melatonin derivative. Melatonin derivatives preferably selected from 5-methoxytryptamine, 5-methoxytryptophan, 5-methoxytryptophol, 5-methoxyindole-3-acetic acid and 6-hydroxy-melatonin. In addition to these substances, they can also be physiologically acceptable Salts, esters and complex compounds thereof are used.

Die zweite Komponente der Zusammensetzung ist Ginkgo Biloba. Ginkgo Biloba besitzt einen positiven Einfluss auf verschiedene Stoffwechselfunktionen. Eine weitere vorteilhafte Eigenschaft von Ginkgo ist die Verstärkung des Radikalfängerpotenzials. Bevorzugt wird ein Ginkgo Biloba als Extrakt, insbesondere als Trockenextrakt, oder/und ein oder mehrere Inhaltsstoffe davon verwendet. Besonders geeignet zur Verwendung der erfindungsgemäßen Zusammensetzung sind Trockenextrakte aus Ginkgo-Blättern.The second component of the composition is Ginkgo Biloba. Ginkgo Biloba has a positive impact on different metabolic functions. Another beneficial one The property of Ginkgo is the strengthening of the radical scavenger potential. A ginkgo biloba is preferred as an extract, in particular as a dry extract, or / and one or more ingredients thereof are used. Particularly suitable for using the composition according to the invention are dry extracts from ginkgo leaves.

Eine weitere Komponente der erfindungsgemäßen Zusammensetzung ist Biotin. Biotin entfaltet seine Wirkung beispielsweise als Coenzym im Fettsäuren- und Aminosäurenstoffwechsel, z.B. bei Transcarboxylierungsreaktionen.Another component of the composition according to the invention is biotin. Biotin works as a coenzyme, for example in fatty acids and amino acid metabolism, e.g. in transcarboxylation reactions.

Die Konzentration der Wirkstoffe in der Zusammensetzung kann – je nach Anwendung – in breiten Bereichen variiert werden. Günstigerweise liegen die Konzentrationen der Wirkstoffe jeweils unabhängig im Bereich zwischen 0,0001 % (Gewicht) bis 1 % (Gewicht) bezogen auf das Gesamtgewicht der Zusammensetzung.The concentration of the active ingredients in the composition - depending after application - in wide ranges can be varied. The concentrations are favorably of the active ingredients each independently in the range between 0.0001% (weight) to 1% (weight) on the total weight of the composition.

Pro Applikation werden bevorzugt etwa 0,001 mg bis etwa 10 mg, bevorzugt etwa 0,01 mg bis etwa 1 mg Melatonin bzw. Melatonin-Derivat verabreicht.Per application are preferred about 0.001 mg to about 10 mg, preferably about 0.01 mg to about 1 mg melatonin or melatonin derivative administered.

Die drei Wirkstoff-Komponenten der erfindungsgemäßen Zusammensetzung entwickeln ein Wirkungsprofil, welches das Haarwachstum fördert, einen Alterungsschutz bereitstellt, die Haardicke verbessert oder/und die Telogenrate reduziert. Die Melatoninwirkung am Haarfollikel wird durch die Kombination mit Ginkgo Biloba und Biotin überraschenderweise verstärkt. Somit können auch sehr niedrige Konzentrationen an Melatonin, beispielsweise etwa 0,001-10 mg, bevorzugt etwa 0,01-1 mg pro Applikation, mit zufriedenstellender Wirkung eingesetzt werden.The three active ingredient components of composition according to the invention develop an effect profile that promotes hair growth, an aging protection provides, improves the hair thickness and / or the telogen rate reduced. The melatonin effect on the hair follicle is due to the combination with ginkgo biloba and biotin surprisingly strengthened. So you can also very low concentrations of melatonin, for example about 0.001-10 mg, preferably about 0.01-1 mg per application, with satisfactory effect.

Die Kombination von Melatonin, Ginkgo Biloba und Biotin kann in einem geeigneten Trägersystem verabreicht werden. Vorzugsweise sind die Wirkstoffe gelöst oder/und dispergiert in einem flüssigen, halbfesten oder festen Trägersystem enthalten. Beispiele für geeignete Trägersysteme sind Flüssigkeiten wie Wasser oder wässrige Pufferlösungen, physiologisch verträgliche organische Lösungsmittel wie Ethanol oder Kombinationen davon, Öl-Wasser-Emulsionen, Wasser-Öl-Emulsionen, Fette, Polyethylenglykole, Propylenglykole, Glycerin, Emulgatoren oder Kombinationen davon sowie andere in pharmazeutischen und kosmetischen Formulierungen verwendete Träger- oder Hilfsstoffe.The combination of melatonin, ginkgo Biloba and biotin can be administered in a suitable carrier system. The active substances are preferably dissolved and / or dispersed in a liquid, semi-solid or solid support system contain. examples for suitable carrier systems are liquids like water or watery Buffer solutions, physiologically acceptable organic solvents such as ethanol or combinations thereof, oil-water emulsions, water-oil emulsions, Fats, polyethylene glycols, propylene glycols, glycerin, emulsifiers or combinations thereof and others in pharmaceutical and cosmetic Formulations used carrier or auxiliary substances.

Diese Trägersysteme ermöglichen vorteilhafterweise eine gezielte Wirkstoffabgabe an das Haarfollikel. Dadurch wird die Wirkstoffplatzierung im Haarfollikel optimiert. Weiterhin kann durch das Trägersystem eine gesteuerte Absorption der Wirkstoffe Melatonin, Ginkgo Biloba und Biotin ermöglicht werden.These carrier systems enable advantageously a targeted release of active ingredient to the hair follicle. This optimizes the placement of the active ingredient in the hair follicle. Furthermore, by the carrier system controlled absorption of the active ingredients melatonin, ginkgo biloba and enables biotin become.

Die Verarbeitung von Melatonin mit Ginkgo Biloba und Biotin in geeigneten Trägersystemen kann darüber hinaus zu einer Verhinderung oder Verzögerung der Melatoninresorption führen. Dadurch wird der normale humane Plasmaspiegel nicht beeinflusst. Zudem kann eine länger anhaltende Wirkung der Wirkstoffe erzielt werden.Processing melatonin with Ginkgo biloba and biotin in suitable carrier systems can also be used to prevent or delay of melatonin absorption. This does not affect the normal human plasma level. In addition, one can last longer lasting effect of the active ingredients can be achieved.

Durch Formulierung in einem Trägersystem können stabile Formulierungen erhalten werden, die in der Kosmetik, insbesondere in Form kosmetischer Lösungen, verwendet werden.By formulation in a carrier system, stable Formulations are obtained that are used in cosmetics, in particular in the form of cosmetic solutions, be used.

Bei Verwendung von speziellen Formulierungssystemen, wie Liposomen, Nanosomen oder festen Einschlussträgern, wie Agarose, können Zusammensetzungen erhalten werden, die eine kontrollierte Abgabe von zumindest einem der Wirkstoffe, insbesondere von allen Wirkstoffen, erlauben.When using special formulation systems, such as liposomes, nanosomes or solid inclusion carriers, such as Agarose, can Compositions are obtained that have a controlled release of at least one of the active substances, in particular of all active substances, allow.

Die erfindungsgemäßen Zusammensetzungen eignen sich insbesondere für pharmazeutische oder/und kosmetische Anwendungen beispielsweise im Haar. Die Zusammensetzungen können als Lösung, Suspension, Emulsion, Mikroemulsion, Nanosystem, Creme, Gel, Lotion, Spray, Schaum oder Salbe oder in jeder anderen für topische Anwendungen geeigneten Form vorliegen. Sie werden überlicherweise in einem Verpackungs- oder Anwendungssystem ausgewählt aus Tuben, Flaschen, Sprayflaschen, Pflastern, Schwämmen und Textil- oder Kunststoffträgern und anderen für die Applikation im Haar geeigneten Systemen eingesetzt. Ein besonders bevorzugtes Verpackungssystem sind Eindosis-Ampullen, welche eine Dosierungseinheit für eine Applikation bereitstellen. Die Ampullen können aus verschiedenen Materialien, z.B. aus Glas oder Kunststoff, gefertigt sein. Besonders bevorzugt sind Kunststoffampullen, da Kunststoffampullen eine sichere und gute Handhabung gewährleisten.The compositions according to the invention are particularly suitable for pharmaceutical or / and cosmetic applications, for example in the hair. The compositions can be in the form of a solution, suspension, emulsion, microemulsion, nanosystem, cream, gel, lotion, spray, foam or ointment or in any other form suitable for topical applications. They are usually used in a packaging or application system selected from tubes, bottles, spray bottles, plasters, sponges and textile or plastic carriers and other systems suitable for application in the hair. A particularly preferred packaging system is single-dose ampoules, which provide a dosage unit for an application. The ampoules can be made from different materials, for example from glass or plastic. Plastic ampoules are particularly preferred because plastic ampoules ensure safe and good handling.

Neben den Wirkstoffen können die erfindungsgemäßen Zusammensetzungen einen oder mehrere kosmetische oder/und pharmazeutische Hilfs- bzw. Zusatzstoffe, beispielsweise Verdickungsmittel, Mineralstoffe, Öle, Vitamine oder Duftstoffe, enthalten.In addition to the active ingredients compositions according to the invention one or more cosmetic or / and pharmaceutical auxiliary or Additives, for example thickeners, minerals, oils, vitamins or fragrances.

Die erfindungsgemäßen Kombinationspräparate werden insbesondere zur Anwendung am Abend empfohlen und entfalten ihre Wirkung insbesondere während der Nachtstunden. Bei dieser Art von Anwendung ist die Wirkung der Zusammensetzung besonders stark. Die erfindungsgemäßen Zusammensetzungen eignen sich insbesondere zur Stimulierung der Haarfollikel und einer positiven Beeinflussung des Haarwachstums.The combination preparations according to the invention are especially recommended for use in the evening and unfold their Effect especially during of the night hours. With this type of application, the effect of Composition particularly strong. The compositions according to the invention are particularly suitable for stimulating the hair follicles and one positively influencing hair growth.

Die Behandlung erfolgt insbesondere in topischen, für die Anwendung im Haar geeigneten Applikationen, welche die entsprechenden, für den jeweiligen Verwendungszweck geeigneten Konzentrationen der Wirkstoffe enthalten.The treatment takes place in particular in topical, for the application in hair suitable applications, which the corresponding, for the appropriate concentrations of the active ingredients for each intended use contain.

Die Erfindung wird weiterhin durch das folgende Beispiel erläutert.The invention is further accomplished by the following example explains.

Beispiel: Zusammensetzung einer erfindungsgemäßen Formulierung mit den Wirkstoffen Melatonin, Ginkgo Biloba und BiotinExample: composition a formulation according to the invention with the active ingredients melatonin, ginkgo biloba and biotin

Die Zusammensetzung enthält 0,05 Gew.-% Ginkgo Biloba Trockenextrakt, 0,01 Gew.-% Biotin, 0,0033 Gew.-% Melatonin sowie weitere Zusatzstoffe, Wasser und Ethanol.The composition contains 0.05 % By weight ginkgo biloba dry extract, 0.01% by weight biotin, 0.0033 % Melatonin and other additives, water and ethanol.

Claims (14)

Zusammensetzung, dadurch gekennzeichnet, dass sie als Wirkstoffe (a) Melatonin oder ein Derivat davon, (b) Ginkgo Biloba und (c) Biotin enthält.Composition, characterized in that it contains as active ingredients (a) melatonin or a derivative thereof, (b) ginkgo biloba and (c) biotin. Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, dass sie Melatonin oder ein Melatonin-Derivat ausgewählt aus 5-Methoxytryptamin, 5-Methoxytryptophan, 5-Methoxytryptophol, 5-Methoxyindol-3-essigsäure und 6-Hydroxy-melatonin sowie physiologisch akzeptable Salze, Ester und Komplexverbindungen davon enthält.Composition according to claim 1, characterized in that they selected from melatonin or a melatonin derivative 5-methoxytryptamine, 5-methoxytryptophan, 5-methoxytryptophol, 5-methoxyindole-3-acetic acid and 6-hydroxy-melatonin and physiologically acceptable salts, esters and contains complex compounds thereof. Zusammensetzung nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass sie Ginkgo Biloba als Trockenextrakt oder/und einen oder mehrere Inhaltsstoffe davon enthält.Composition according to claim 1 or 2, characterized in that they have ginkgo biloba as a dry extract or / and one or more Contains ingredients of it. Zusammensetzung nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass die Konzentration oder Wirkstoffe jeweils im Bereich zwischen 0,0001 % (Gewicht) und 1 % (Gewicht) bezogen auf das Gesamtgewicht der Zusammensetzung liegt.Composition according to one of the preceding claims, characterized characterized in that the concentration or active ingredients in each case Range between 0.0001% (weight) and 1% (weight) based on the total weight of the composition is. Zusammensetzung nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass die Wirkstoffe gelöst oder/und dispergiert in einem flüssigen, halbfesten oder festen Trägersystem vorliegen.Composition according to one of the preceding claims, characterized characterized in that the active ingredients dissolved and / or dispersed in a liquid, semi-solid or solid support system available. Zusammensetzung nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass sie eine kontrollierte Abgabe von zumindest einem der Wirkstoffe erlaubt.Composition according to one of the preceding claims, characterized characterized that they have a controlled delivery of at least allowed one of the active ingredients. Zusammensetzung nach einem der vorhergehenden Ansprüche für pharmazeutische oder/und kosmetische Anwendungen.Composition according to one of the preceding claims for pharmaceutical or / and cosmetic applications. Zusammensetzung nach Anspruch 6 zur Anwendung im Haar.Composition according to claim 6 for use in Hair. Zusammensetzung nach Anspruch 8, dadurch gekennzeichnet, dass die transdermale Absorption von zumindest einem der Wirkstoffe steuerbar ist.Composition according to claim 8, characterized in that the transdermal absorption of at least one of the active ingredients is controllable. Zusammensetzung nach einem der vorhergehenden Ansprüche als Lösung, Suspension, Emulsion, Mikroemulsion, Nanosystem, Creme, Gel, Lotion, Spray, Schaum oder Salbe.Composition according to one of the preceding claims as Solution, Suspension, emulsion, microemulsion, nanosystem, cream, gel, lotion, Spray, foam or ointment. Zusammensetzung nach einem der vorhergehenden Ansprüche in einem Verpackungs- oder Anwendungssystem ausgewählt aus Eindosis-Ampullen aus Kunststoff oder Glas, Tuben, Flaschen, Sprayflaschen, Pflastern, Schwämmen und Textil- oder Kunststoffträgern.Composition according to one of the preceding claims in one Packaging or application system selected from single dose ampoules Plastic or glass, tubes, bottles, spray bottles, plasters, sponges and textile or plastic carriers. Zusammensetzung nach einem der vorhergehenden Ansprüche zur Verstärkung der Haarfollikel-stimulierenden Wirkung von Melatonin durch den Zusatz von Ginkgo Biloba und Biotin.Composition according to one of the preceding claims reinforcement the hair follicle stimulating effect of melatonin by the addition by Ginkgo Biloba and Biotin. Verwendung einer Zusammensetzung nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass pro Applikation 0,001 mg bis 10 mg Melatonin verabreicht werden.Use of a composition according to one of the preceding claims, characterized in that 0.001 mg to 10 per application mg melatonin can be administered. Verwendung nach Anspruch 13, dadurch gekennzeichnet, dass pro Applikation 0,01 mg bis bis 1 mg Melatonin verabreicht werden.Use according to claim 13, characterized in that 0.01 mg to 1 mg melatonin administered per application become.
DE10250646A 2002-10-30 2002-10-30 Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents Withdrawn DE10250646A1 (en)

Priority Applications (56)

Application Number Priority Date Filing Date Title
DE10250646A DE10250646A1 (en) 2002-10-30 2002-10-30 Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents
ES03769477.5T ES2353865T5 (en) 2002-10-30 2003-10-30 Melatonin daily dosage units
AU2003283327A AU2003283327A1 (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
RU2005116263/15A RU2336873C2 (en) 2002-10-30 2003-10-30 Melatonin daily dose dosimeters
CNA2003801023960A CN1708331A (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
BR0315878-0A BR0315878A (en) 2002-10-30 2003-10-30 Melatonin in Cosmetic Formulations
US10/533,517 US20060035924A1 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
CA002504361A CA2504361A1 (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
CN2011101545581A CN102283835A (en) 2002-10-30 2003-10-30 Melatonin daily dosage units
EP03769477.5A EP1562585B2 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
NZ539871A NZ539871A (en) 2002-10-30 2003-10-30 Daily melatonin dosing units of 0.01 to 0.2 mg of melatonin or melatonin derivative, for promoting hair growth
PCT/EP2003/012097 WO2004039454A1 (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
CNA200380102359XA CN1708301A (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
PT03775265T PT1569724E (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
AT03769477T ATE489073T1 (en) 2002-10-30 2003-10-30 MELATONIN DAILY DOSAGE UNITS
AT03775265T ATE419038T1 (en) 2002-10-30 2003-10-30 FORMULATIONS CONTAINING MELATONIN, GINKGO BILOBA AND BIOTIN
CN2009102541491A CN101897736A (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
ES03775265T ES2315541T3 (en) 2002-10-30 2003-10-30 FORMULATIONS CONTAINING MELATONINE, GINKGO BILOBA AND BIOTINE.
PT03769477T PT1562585E (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
DK03769477.5T DK1562585T3 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
PCT/EP2003/012099 WO2004039369A1 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
US10/533,516 US8062648B2 (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
EP03775265A EP1569724B1 (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
JP2005501815A JP2006510556A (en) 2002-10-30 2003-10-30 Melatonin-daily dose unit
NZ539872A NZ539872A (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
AU2003278164A AU2003278164A1 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
JP2005501814A JP2006513255A (en) 2002-10-30 2003-10-30 Preparations containing melatonin, ginkgo and biotin
SI200331508T SI1569724T1 (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
PL376226A PL224878B1 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
MXPA05004535A MXPA05004535A (en) 2002-10-30 2003-10-30 Daily melatonin dosing units.
DE50313285T DE50313285D1 (en) 2002-10-30 2003-10-30 MELATONIN DAILY DOSAGE UNITS
CA002504341A CA2504341A1 (en) 2002-10-30 2003-10-30 Melatonin daily dosing units
BR0315927-2A BR0315927A (en) 2002-10-30 2003-10-30 Single dose daily melatonin units
MXPA05004537A MXPA05004537A (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin.
RU2005116264/15A RU2336890C2 (en) 2002-10-30 2003-10-30 Compounds containing melatonin, ginkgo biloba and biotin
SI200331934T SI1562585T1 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
DK03775265T DK1569724T3 (en) 2002-10-30 2003-10-30 Formulations containing melatonin, gingko biloba and biotin
KR1020057007293A KR100849916B1 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
KR1020057007281A KR20050083836A (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba and biotin
DE50311024T DE50311024D1 (en) 2002-10-30 2003-10-30 FORMULATIONS CONTAINING MELATONIN, GINKGO BILOBA AND BIOTIN
PL375507A PL212984B1 (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
IS7820A IS7820A (en) 2002-10-30 2005-04-25 Compositions containing melatonin, temple and biotin
TNP2005000118A TNSN05118A1 (en) 2002-10-30 2005-04-27 Daily melatonin dosing units
TNP2005000117A TNSN05117A1 (en) 2002-10-30 2005-04-27 Formulations containing melatonin, ginkgo biloba, and biotin
IL168288A IL168288A (en) 2002-10-30 2005-04-28 Formulations containing melatonin, ginkgo biloba and biotin for promoting hair growth
IL168287A IL168287A (en) 2002-10-30 2005-04-28 Disposable medicament/cosmetic container for topical application and arrangements and package units comprising the same
HR20050385A HRP20050385A2 (en) 2002-10-30 2005-04-29 Formualations containing melatinon, ginkgo biloba, and biotin
HR20050386A HRP20050386A2 (en) 2002-10-30 2005-04-29 Daily melatonin dosing units
CR7819A CR7819A (en) 2002-10-30 2005-04-29 UNIT FOR DAILY DOSAGE OF MELATONIN
NO20052494A NO334680B1 (en) 2002-10-30 2005-05-24 Compositions such as topical formulation for use in hair containing melatonin, gingko biloba and biotin as well as its use.
NO20052490A NO335547B1 (en) 2002-10-30 2005-05-24 Disposable container containing drug or cosmetic for topical application, multiple container assembly and packaging unit comprising multiple devices.
EC2005005820A ECSP055820A (en) 2002-10-30 2005-05-26 UNIT FOR DAILY DOSAGE OF MELATONIN
EC2005005819A ECSP055819A (en) 2002-10-30 2005-05-26 FORMULATIONS CONTAINING MELATONINE, GINKGO BILOBA AND BIOTINE
HK05107183.7A HK1074793A1 (en) 2002-10-30 2005-08-18 Daily melatonin dosing units
US12/116,484 US8017645B2 (en) 2002-10-30 2008-05-07 Melatonin daily dosage units
CY20111100147T CY1111179T1 (en) 2002-10-30 2011-02-09 Daily melatonin dosage units

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10250646A DE10250646A1 (en) 2002-10-30 2002-10-30 Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents

Publications (1)

Publication Number Publication Date
DE10250646A1 true DE10250646A1 (en) 2004-05-13

Family

ID=32103188

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10250646A Withdrawn DE10250646A1 (en) 2002-10-30 2002-10-30 Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents

Country Status (3)

Country Link
DE (1) DE10250646A1 (en)
ES (1) ES2353865T5 (en)
TN (2) TNSN05118A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017021247A1 (en) * 2015-07-31 2017-02-09 Isdin, S.A. Anti-hair loss lotion

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11877981B2 (en) 2018-12-05 2024-01-23 The Procter & Gamble Company Container for personal health compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952373A (en) * 1994-12-13 1999-09-14 Beiersdorf Ag Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
US20020061870A1 (en) * 2000-01-27 2002-05-23 Pearson Don C. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952373A (en) * 1994-12-13 1999-09-14 Beiersdorf Ag Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
US20020061870A1 (en) * 2000-01-27 2002-05-23 Pearson Don C. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017021247A1 (en) * 2015-07-31 2017-02-09 Isdin, S.A. Anti-hair loss lotion

Also Published As

Publication number Publication date
ES2353865T3 (en) 2011-03-07
TNSN05118A1 (en) 2007-05-14
TNSN05117A1 (en) 2007-05-14
ES2353865T5 (en) 2017-10-10

Similar Documents

Publication Publication Date Title
EP1569724B1 (en) Formulations containing melatonin, ginkgo biloba, and biotin
DE69732977T2 (en) STABILIZED ASCORBYL COMPOSITIONS
DE602005002844T3 (en) REVERSE REPULSION COMPOSITION WITH CALCITRIOL AND CLOBETASOL-17-PROPIONATE AND THEIR COSMETIC AND DERMATOLOGICAL USE
EP0658097B1 (en) Deodorizing cosmetics containing fatty acids
EP0343694B1 (en) Agent for the treatmment and protection of the skin
DE60224928T2 (en) DERMATOLOGICAL AND COSMETIC COMPOSITIONS CONTAINING A FURFURYL DERIVATIVE
US5002760A (en) Retinol skin care composition
DE60124777T2 (en) ANTIOXIDANT IN WATER MOLECULAR COLLECTIONS
DE60122927T2 (en) SKIN CREAM COMPOSITION
DE69818806T2 (en) ANTIMICROBIAL COSMETIC PREPARATIONS
DD298352A5 (en) TRETINOINE CONTAINING PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
DE69724629T2 (en) COMPOSITIONS AND THEIR USE
DE60110330T2 (en) Diosgenin and caffeine-containing cosmetic composition
DE10155200A1 (en) Use of cholesterol, substances containing cholesterol or substances that increase cholesterol in cosmetic and dermatological preparations for the purpose of UV protection
DE602005003138T3 (en) SPRAYFORM COMPOSITION COMPRISING A CLOBETASOLPROPIONATE AND CALCITRIOL COMBINATION, ALCOHOL PHASE AND OIL PHASE
DE2601489C2 (en)
DE69829838T2 (en) PROCESS FOR STABILIZING LEFT-ROTATING ASCORBIC ACID (LAA) AND STABLE COMPOSITIONS OF LAA
JPH06336423A (en) External agent for skin
WO2006122668A1 (en) Active ingredient combinations of glucosyl glycerides and creatine and/or creatinine
WO2010009809A2 (en) Active substance combinations consisting of an anis fruit extract and hyaluronic acid
JPH06336422A (en) External agent for skin
DE10250646A1 (en) Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents
DE1668171A1 (en) PROCESS FOR THE PRODUCTION OF STABLE Aqueous SOLUTIONS OF NEW COMPLEX ORGANOSILICIUM COMPOUNDS
EP2072038A2 (en) Active agent combinations made from aniseed fruit extract and one or more 2,3-dibenzyl butyrolactones
DE10110418A1 (en) Melatonin Vitamin A supplements

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8110 Request for examination paragraph 44
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20110502